Rallybio Unveils Promising Therapies RLYB212 and RLYB332 at ASH Annual Meeting

Rallybio Showcases Innovative Therapies at ASH Annual Meeting

Rallybio Corporation, a clinical-stage biotechnology company dedicated to developing therapies for rare diseases, highlights significant advancements in its research pipeline at the 66th American Society of Hematology (ASH) Annual Meeting. Scheduled for December 7–10, 2024, in San Diego, California, the meeting serves as a platform for Rallybio to present promising preclinical data on its therapeutic candidates RLYB212 and RLYB332. These findings underscore the company’s commitment to addressing unmet medical needs in maternal and pediatric health as well as iron overload conditions.

The ongoing Phase 2 trial of RLYB212 specifically targets pregnant women at risk for maternal alloimmunization and fetal/neonatal alloimmune thrombocytopenia (FNAIT). Data presented indicate that RLYB212, administered at doses of 1.01 or 5.05 µg/kg to pregnant mice, successfully prevents maternal alloimmunization and maintains normal platelet counts in offspring. This crucial evidence positions RLYB212 as a promising prophylactic treatment, aiming to enhance maternal and fetal health outcomes. The absence of thrombocytopenia in the pups further strengthens the safety profile of RLYB212, a critical factor for any therapeutic intended for use in vulnerable populations.

In addition to RLYB212, Rallybio also showcases RLYB332, a long-acting anti-matriptase-2 antibody that demonstrates significant pharmacodynamic effects on serum iron levels. In humanized FcRn mice, RLYB332 exhibits a capacity to reduce serum iron levels and improve transferrin saturation, surpassing the efficacy of existing treatments for iron overload diseases. The preliminary results suggest that RLYB332 could emerge as a best-in-class therapy, and its favorable tolerability in preclinical models adds to its therapeutic potential. These developments highlight Rallybio’s innovative approach to tackling complex medical challenges associated with both maternal health and iron metabolism disorders.

Beyond these key presentations, Rallybio’s commitment to advancing rare disease therapies stands out as a core aspect of its mission. The detailed findings from the ASH meeting not only contribute to the scientific community's understanding of these conditions but also provide hope for patients and families impacted by these severe health challenges. The anticipation surrounding the presentations of RLYB212 and RLYB332 reflects Rallybio's role as a leader in the biotechnology sector focused on transformative solutions for rare and critical health issues.